Show simple item record

dc.contributor.authorContoyannis, P
dc.contributor.authorHurley, J
dc.contributor.authorGrootendorst, P
dc.contributor.authorJeon, SH
dc.contributor.authorTamblyn, R
dc.date.available2014-05-21T20:46:11Z
dc.date.issued2005-09-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000232210600004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4d813f4571fa7d6246bdc0dfeca3a1c
dc.identifier.citationContoyannis, P., Hurley, J., Grootendorst, P., Jeon, S. H. & Tamblyn, R. (2005). Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. HEALTH ECONOMICS, 14 (9), pp.909-923. https://doi.org/10.1002/hec.1041.
dc.identifier.issn1057-9230
dc.identifier.urihttp://hdl.handle.net/11343/27767
dc.descriptionC1 - Refereed Journal Article
dc.description.abstractThe price elasticity of demand for prescription drugs is a crucial parameter of interest in designing pharmaceutical benefit plans. Estimating the elasticity using micro-data, however, is challenging because insurance coverage that includes deductibles, co-insurance provisions and maximum expenditure limits create a non-linear price schedule, making price endogenous (a function of drug consumption). In this paper we exploit an exogenous change in cost-sharing within the Quebec (Canada) public Pharmacare program to estimate the price elasticity of expenditure for drugs using IV methods. This approach corrects for the endogeneity of price and incorporates the concept of a 'rational' consumer who factors into consumption decisions the price they expect to face at the margin given their expected needs. The IV method is adapted from an approach developed in the public finance literature used to estimate income responses to changes in tax schedules. The instrument is based on the price an individual would face under the new cost-sharing policy if their consumption remained at the pre-policy level. Our preferred specification leads to expenditure elasticities that are in the low range of previous estimates (between -0.12 and -0.16). Naïve OLS estimates are between 1 and 4 times these magnitudes.
dc.languageEnglish
dc.publisherWILEY
dc.subjectApplied Economics
dc.titleEstimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada
dc.typeJournal Article
dc.identifier.doi10.1002/hec.1041
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentMelbourne Institute Of Applied Economic And Social Research
melbourne.source.titleHEALTH ECONOMICS
melbourne.source.volume14
melbourne.source.issue9
melbourne.source.pages909-923
dc.research.codefor1402
melbourne.publicationid52202
melbourne.elementsid277421
melbourne.contributor.authorJEON, SUNG-HEE
dc.identifier.eissn1099-1050
melbourne.conference.locationUniv Rome Tor Vergata, Rome, ITALY
melbourne.accessrightsThis item is currently not available from this repository


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record